Clinical Study

A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes

Shuo Lin,1 Mu Chen,2 Wanling Chen,3 Keyi Lin,1 Panwei Mu,1 Bilian Zhu,1 Wen Xu,1 Manman Wang,1 Jianping Weng,1 and Longyi Zeng1

1Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Lu, Guangzhou 510630, China
2Respiratory Department, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China
3Department of Endocrinology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China

Correspondence should be addressed to Longyi Zeng; zengly@mail.sysu.edu.cn

Received 20 July 2018; Revised 5 September 2018; Accepted 13 September 2018; Published 21 October 2018

Academic Editor: Maria Rosaria Rizzo

Copyright © 2018 Shuo Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. Basal insulin plus oral hypoglycemic agents (OHAs) has not been investigated for early intensive antihyperglycemic treatment in people with newly diagnosed type 2 diabetes. This study is aimed at comparing the short-term (over a period of 12 days) effects of basal insulin glargine plus OHAs and continuous subcutaneous insulin infusion (CSII) on glycemic control and beta-cell function in this setting.

Methods. An open-label parallel-group study. Newly diagnosed hospitalized patients with type 2 diabetes and fasting plasma glucose (FPG) ≥11.1 mmol/L or glycated hemoglobin (HbA1c) ≥9% (75 mmol/mol) were randomized to CSII or insulin glargine in combination with metformin and gliclazide. The primary outcome measure was the mean amplitude of glycemic excursions (MAGE), and secondary endpoints included time to reach glycemic control target (FPG < 7 mmol/L and 2-hour postprandial plasma glucose < 10 mmol/L), markers of β-cell function, and hypoglycemia.

Results. Subjects in the CSII (n = 35) and basal insulin plus OHA (n = 33) groups had a similar significant reduction from baseline to end of treatment in glycated albumin (−6.44 ± 3.23% and− 6.42 ± 3.56%, P = 0.970). Groups A and B have comparable time to glycemic control (3.6 ± 1.2 days and 4.0 ± 1.4 days), MAGE (3.40 ± 1.40 mmol/L vs. 3.16 ± 1.38 mmol/L; p = 0.484), and 24-hour mean blood glucose (7.49 ± 0.96 mmol/L vs. 7.02 ± 1.03 mmol/L). Changes in the C-peptide reactivity index, the secretory unit of islet in transplantation index, and insulin secretion-sensitivity index-2 indicated a greater β-cell function improvement with basal insulin plus OHAs versus CSII. Conclusions. Short-term insulin glargine plus OHAs may be an alternative to CSII for initial intensive therapy in people with newly diagnosed type 2 diabetes.

1. Introduction

The progressive nature of type 2 diabetes mellitus is ascribed to a vicious cycle of increasing insulin resistance and progressive pancreatic islet β-cell dysfunction [1, 2], caused by the toxic effects of hyperglycemia and gluco-lipotoxicity [3]. Substantial evidences showed that in people with type 2 diabetes, nearly 50% of β-cell function is lost by the time of diagnosis, and this loss continues over time irrespective of lifestyle and pharmacological intervention [4]. Recent studies have suggested that early intensive glucose-lowering therapies are effective for managing blood glucose levels and sustaining β-cell function and have the long-term benefit of reducing the development of both micro- and macrovascular complications [5–7]. Of these intensive regimens, insulin-based protocols, such as continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI), are highly effective at reducing hyperglycemia in patients with poorly controlled type 2 diabetes [8–11]. A meta-analysis of individuals receiving intensive hyperglycemia-reducing regimens showed a significant increase in β-cell function and a decrease in insulin resistance, with 46.3% of patients in remission after 12
months without the use of medication and relying solely on lifestyle modification to control blood glucose levels [12]. Two to five weeks of CSII can reduce gluco-toxicity, ameliorate insulin resistance, and promote recovery of \( \beta \)-cell function in subjects with newly diagnosed type 2 diabetes [13, 14].

However, CSII has shortcomings, with high cost, inconvenience, and relatively complex equipment limiting its uptake by people with type 2 diabetes. Moreover, the need for frequent glucose monitoring during intensive short-term CSII makes implementation in the out-patient setting relatively impractical [15]. Similarly, the MDI approach has limitations such as the need for multiple injections and difficulties with implementation in the out-patient setting. In contrast, basal insulin plus oral hypoglycemic agents (OHAs) has advantages over CSII and MDI including the possibility for convenient once-daily injections [16, 17]. For people with type 2 diabetes poorly controlled by metformin, early addition of the long-acting insulin analogue insulin glargine leads to effective glycemic control and improved \( \beta \)-cell function [18, 19]. Indeed, both the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) advocate such regimens for patients with type 2 diabetes who have severe hyperglycemia [20].

In newly diagnosed individuals with type 2 diabetes, short-term use of insulin glargine monotherapy showed non-inferior efficacy when compared with CSII in terms of fasting glycemic control and recovery of \( \beta \)-cell function. However, postprandial glycemic excursions were less well controlled with insulin glargine versus CSII [21]. Basal insulin plus OHAs may be expected to exert similar or better glycemic control over both fasting and postprandial glucose levels, with improved \( \beta \)-cell function. However, while previous studies have investigated and compared CSII, MDI, OHAs, or insulin glargine monotherapy as short-term intensive treatment for people recently diagnosed with type 2 diabetes, basal insulin plus OHAs has not been investigated. This report describes a randomized open-label parallel-group trial of short-term (over a period of 12 days) intensive hypoglycemic therapy with basal insulin (glargine) plus OHAs, compared with CSII treatment, in patients with newly diagnosed type 2 diabetes mellitus, which is aimed at assessing the acute effects of these treatment approaches on glycemic control and \( \beta \)-cell function.

2. Methods

2.1. Patients. Participants aged 25–70 years old with newly diagnosed type 2 diabetes mellitus (according to the 1999 WHO diagnostic criteria [22]) with fasting plasma glucose (FPG) \( \geq 11.1 \) mmol/L or HbA1c \( \geq 9\% \) (75 mmol/mol), who were hospitalized between November 2014 and November 2015, and had not previously received medication for diabetes were eligible for inclusion. Patients were excluded if they tested positive for autoimmune antibodies to islet cells, were pregnant or breast-feeding, had acute or chronic complications of diabetes, had chronic heart failure, had impaired renal function or clinically evident hepatic disease, acute infection, took drugs which may affect glucose metabolism (corticosteroids, antipsychotics, immunosuppressive drugs, etc.), or would not confirm that they would comply with the study protocol. All patients gave written informed consent for enrollment into the study, which was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat-sen University. This study was registered at ClinicalTrials.gov (NCT02526810).

2.2. Study Design and Treatment. This was an open-label, single-center, randomized, parallel-group, noninferiority trial conducted at The Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, Guangdong, China). All subjects were hospitalized throughout the study and were addressed in an educational training. Patients were provided with balanced diets for diabetes, recommended taking 30 minutes of physical exercise after meals, and educated on diabetes self-management. Patients were randomly assigned (1 : 1) to either CSII monotherapy (group A) or basal insulin plus OHA (group B). Randomization was performed using sealed and opaque envelopes arranged in a computer-generated random order, prepared by specific staff and opened sequentially to determine the patients’ treatment assignments. Patients in group A received a fast-acting insulin analog (insulin Aspart, Novo Nordisk, Bagsvaerd, Denmark) as basal medication and prandial insulin administered via an insulin pump (Paradigm 722, Medtronic, Minneapolis, MN). Patients in group B received insulin glargine (Lantus, Sanofi-Aventis, Paris, France) injection once daily at bedtime, oral metformin (Glucophage) 0.5g twice daily, and gliclazide (Diamicron MR) 60 mg each morning. Total initial insulin doses were 0.5–0.8IU/kg for the CSII group (including basal and bolus insulin, 1 : 1) and 0.2IU/kg for the basal insulin plus OHA group. Insulin doses were titrated every day by doctors using a glycemic target defined as fasting capillary blood glucose <7 mmol/L and 2-hour postprandial blood glucose <10 mmol/L. The basal insulin dosage was given by using the titration algorithm based on FPG (Supplementary Materials (available here)). Metformin was added gradually to a maximum dose of 1g twice daily unless intolerable, in which case a lower dose could be administered. Gliclazide was added to 90 mg or 120 mg by doctors while 2-hour postprandial blood glucose \( \geq 10 \) mmol/L with fasting capillary blood glucose <7 mmol/L.

2.3. Endpoints. The primary study endpoint was mean amplitude of glycemic excursions (MAGE) after reaching glycemic target. Secondary endpoints included time to reach glycemic target (fasting capillary blood glucose <7 mmol/L and 2-hour postprandial plasma glucose (PPG) <10 mmol/L), change of HbA1c, fasting plasma glucose (FPG), PPG, glycated albumin, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides, assessment of glycemic excursions, pre- and postprandial mean blood glucose level (MBG), levels of insulin secretion, C-peptide levels, assessment of \( \beta \)-cell function, and incidence of hypoglycemia.

2.4. Assessments. Demographic data were recorded on enrollment. A standard mixed meal tolerance test was performed.
in the fasted state before the start and at the end of the study with 0, 30, and 120-minute blood samples collected. The meal comprised 562 kcal with 51.2% carbohydrates, 33.4% lipids, and 15.4% protein and was consumed over 15 minutes. During the study, capillary blood glucose was monitored at least seven times a day (before, and 2 hours after, each meal and at bedtime) using a blood glucometer (OneTouch Ultra, LifeScan, Milpitas, CA). Normoglycemia was confirmed for 1 to 3 days after the glycemic target was achieved, and then, a continuous glucose monitoring system (Medtronic Paradigm, 722) was used to monitor glycemic variability for 72 hours before study treatment was stopped. After stopping the treatment in group A (for more than 12 hours) and group B (metformin and glitazide for more than 24 hours, glargine for more than 36 hours), a standard mixed meal tolerance test was performed and blood samples were collected in each subject as well as baseline. Venous blood was drawn for measurement of FPG and PPG, HbA1c, glycated albumin, lipid profile, fasting and postprandial C-peptide and insulin, and routine clinical laboratory analyses. Plasma glucose was measured using the glucose oxidase method. Plasma triglycerides, total cholesterol, HDL-C, and LDL-C were measured using an automatic oxide test. HbA1c was measured using the Bio-Rad (Hercules, CA) Variant HbA1c assay. Plasma insulin and C-peptide levels were measured with a chemiluminescence enzyme-linked immunosorbent assay (Bioenk, Inc., Beijing, China). Proinsulin was measured using the Total Human Proinsulin ELISA kit (EMD Millipore, USA). Laboratory tests were performed in the central clinical laboratory of the Third Affiliated Hospital of Sun Yat-sen University.

The area under the curve (AUC) for insulin, glucose, and C-peptide during the standard mixed meal tolerance test was calculated using the trapezoidal rule. A homeostasis model assessment of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β) was used to estimate insulin sensitivity and β-cell function [23], and the Matsuda index was used to evaluate whole body insulin sensitivity [24]. The secretary unit of islet in transplantation (SUIT) index and C-peptide reactivity index (CPI) were used to estimate β-cell function [25, 26]. Early-phase insulin secretion in response to glucose was assessed using the insulinogenic index (∆insulin0.5h/∆glucose0.5h), calculated as the incremental insulin response (0–30 minutes) divided by the incremental glucose response (0–30 minutes) [27]. The insulin secretion-sensitivity index-2 (ISSI-2) was also used as a validated measurement of β-cell function ([AUC insulin/AUC glucose] × Matsuda index) [9, 28]. The ratio of proinsulin to immunoreactive insulin (PI/IRI) was also calculated as a marker of β-cell function.

Glucose fluctuation parameters such as MAGE, standard deviation of blood glucose levels (SDBG), MBG, proportion of the time in hyperglycemia (>7.8 mmol/L), proportion of the time in hypoglycemia (<3.9 mmol/L), 1-hour fasting MBG, and 3-hour postprandial MBG, were assessed by continuous glucose monitoring [29]. The MAGE was manually calculated as the mean of differences between consecutive peaks and nadirs, with excursions < 1 standard deviation excluded. Change in BMI after treatment, the time and medication dose required to reach glycemic targets, and hypoglycemia occurrence were recorded. Hypoglycemia was defined as blood glucose < 3.9 mmol/L with or without clinical symptoms. A severe hypoglycemic episode was defined as a hypoglycemic event requiring the assistance of another person.

2.5. Statistical Analyses. Based on previous research, this noninferiority study was powered to detect an intergroup difference in MAGE of 0.3 mmol/L assuming a standard deviation of 0.5 mmol/L, type 1 error of 0.05, and type 2 error of 0.2. Using these assumptions, a sample size of 34.4 patients in each group was calculated, giving a total enrolment target of 70 patients.

Descriptive variables were compared between groups using an unpaired Student’s t-test for parametric data and the Mann–Whitney U test for nonparametric data. Repeated measurements were assessed using a sample-paired Student's t-test and Wilcoxon matched pair test for nonparametric data. To compare the treatment effect on MAGE between the two groups, the analysis of covariance (ANCOVA) was used, with treat groups as the fixed main effect, and mean capillary blood glucose (seven-point) at baseline as the covariate. Pearson’s (parametric data) or Spearman’s (non-parametric data) tests were used to detect correlations between variables. All statistical procedures were processed using SPSS software for Windows version 19.0. (SPSS Inc., Chicago, IL). A two-sided p value of < 0.05 was considered statistically significant.

3. Results

3.1. Patients. A total of 79 patients with newly diagnosed type 2 diabetes mellitus were assessed for suitability for the study, and 71 were randomized to treatment (group A, n = 36; group B, n = 35) (Supplementary Figure 1). One patient randomized to group A left the study early for financial reasons and two in Group B left early due to gout (n = 1) and personal circumstance (n = 1). The final analysis population therefore included 68 patients (35 in group A and 33 in group B).

Baseline demographic characteristics of study subjects were comparable between the two groups, with similar mean age (group A, 47.6 ± 10.9 years; group B, 49.0 ± 9.9 years), proportion of males (group A, 71.4%; group B, 69.7%), and BMI (group A, 25.4 ± 3.7 kg/m²; group B, 25.3 ± 2.8 kg/m²). Laboratory parameters at baseline were also generally comparable between the two groups, with the exception of triglyceride levels which were higher for subjects in group B (1.51 ± 0.70 vs. 2.19 ± 1.23 mmol/L, p = 0.006) (Table 1). No differences were observed between baseline values of glucose assessment parameters (HbA1c, glycated albumin, FPG, and PPG), PI/IRI, or indices of β-cell secretion (CPI, SUIT, ∆INS0.5h/∆GLU0.5h, and ISSI-2) (Tables 1 and 2). Baseline HOMA index was also comparable between the two groups. There was no significant difference in mean capillary blood glucose (seven-point/day) at baseline between group A (13.6 ± 2.5 mmol/L) and group B (14.2 ± 3.4 mmol/L) (P = 0.389).
Table 1: Glycemic and lipid assessment parameters from baseline to the end of study treatment with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B).

| Clinical characteristic | Group A (n = 35) | Group B (n = 33) | P value |
|-------------------------|-----------------|-----------------|---------|
| Age                     | 47.6 ± 10.9     | 49.0 ± 9.9      | 0.590   |
| Male (n, %)             | 25, 71.4        | 23, 69.7        | 0.876   |
| BMI (kg/m²)             | 25.4 ± 3.7      | 25.3 ± 2.8      | 0.839   |
| WC (cm)                 | 90.9 ± 8.0      | 90.8 ± 8.2      | 0.937   |
| Baseline HbA1c (%) [mmol/mol] | 11.38 ± 2.00 [100.9] | 11.17 ± 2.00 [98.6] | 0.671   |
| ΔHbA1c (%) [mmol/mol]   | −0.94 ± 0.50†  | −0.80 ± 0.35†  | 0.190   |
| Baseline glycated albumin (%) | 32.70 ± 7.00  | 31.74 ± 9.04  | 0.625   |
| ΔGlycated albumin (%)   | −6.44 ± 3.23‡  | −6.42 ± 3.56‡  | 0.970   |
| Baseline FPG (mmol/L)   | 12.72 ± 2.87    | 12.41 ± 3.33   | 0.681   |
| ΔFPG (mmol/L)           | −5.85 ± 2.92‡  | −7.41 ± 3.41‡  | 0.046   |
| Baseline 2-hour PPG (mmol/L) | 21.73 ± 3.93  | 20.79 ± 4.93  | 0.389   |
| Δ2-hour PPG (mmol/L)    | −7.19 ± 4.18‡  | −9.78 ± 4.94‡  | 0.022   |
| Baseline LDL-C (mmol/L) | 3.44 ± 1.24     | 3.48 ± 1.06    | 0.905   |
| ΔLDL-C (mmol/L)         | −0.76 ± 0.95‡  | −1.04 ± 0.91‡  | 0.221   |
| Baseline total cholesterol (mmol/L) | 5.21 ± 1.27 | 5.63 ± 1.21 | 0.165   |
| ΔTotal cholesterol (mmol/L) | −0.95 ± 0.97‡  | −1.43 ± 1.02‡  | 0.054   |
| Baseline HDL-C (mmol/L) | 1.09 ± 0.25     | 1.17 ± 0.40    | 0.289   |
| ΔHDL-C (mmol/L)         | −0.03 ± 0.16    | −0.10 ± 0.15†  | 0.087   |
| Baseline triglycerides (mmol/L) | 1.51 ± 0.70 | 2.19 ± 1.23 | 0.006   |
| ΔTriglycerides (mmol/L) | −0.10 ± 0.64    | −0.50 ± 1.08†  | 0.062   |

†Data are mean (standard deviation) unless otherwise stated; ‡significant change from baseline (p < 0.05). Δ: change from baseline; BMI: body mass index; WC: waist circumference; FPG: fasting plasma glucose; PPG: postprandial plasma glucose; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.

Table 2: Changes in β-cell function and insulin sensitivity from baseline to day 12 in patients treated with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B).

| Indices | Group A (n = 35) | Group B (n = 33) | P value for group comparison |
|---------|-----------------|-----------------|-----------------------------|
| Baseline AUC insulin (h-mU/L) | 35.83 ± 24.99 | 36.34 ± 23.21 | 0.932 |
| ΔAUC (h-mU/L)‡ | 19.59 (6.50–31.19) | 27.24 (14.49–51.83) | 0.060 |
| Baseline AUC C-peptide (h-nmol/L) | 1.50 ± 0.70 | 1.46 ± 0.62 | 0.826 |
| ΔAUC C-peptide (h-nmol/L)‡ | 0.45 (−0.04–0.72)§ | 0.62 (0.21–1.05)§ | 0.323 |
| Baseline LnHOMA-IR | 1.43 ± 0.48 | 1.30 ± 0.62 | 0.355 |
| ΔLnHOMA-IR | −0.56 ± 0.63§ | −0.33 ± 0.53§ | 0.113 |
| Baseline LnHOMA-β | 2.85 ± 0.77 | 2.81 ± 0.90 | 0.828 |
| ΔLnHOMA-β | 1.06 ± 0.82§ | 2.36 ± 0.98§ | 0.000 |
| Baseline CPI | 0.70 ± 0.43 | 0.72 ± 0.39 | 0.867 |
| ΔCPI | 0.34 ± 0.32§ | 0.74 ± 0.49§ | 0.000 |
| Baseline SUIT | 15.76 ± 12.36 | 16.22 ± 10.39 | 0.870 |
| ΔSUIT | 18.01 ± 12.31§ | 63.99 ± 47.70§ | 0.000 |
| Baseline IG 30 minutes | 1.91 ± 2.19 | 1.56 ± 1.66 | 0.464 |
| ΔIG 30 minutes | 1.33 ± 3.00§ | 2.64 ± 2.64§ | 0.06 |
| Baseline ISSI-2‡ | 49.76 (38.39–75.68) | 63.90 (36.51–113.25) | 0.568 |
| ΔISSI-2‡ | 136.30 (109.22–184.83)§ | 212.51 (168.25–268.80)§ | 0.000 |
| Baseline PI/IRI %‡ | 36.0 (24.9–64.6) | 37.9 ± 24.5 | 0.401 |
| ΔPI/IRI%‡ | −21.8 (−35.6–4.9)§ | −26.5 ± 24.6§ | 0.432 |

†Data are mean (standard deviation) unless otherwise stated; ‡median (range); §significant change from baseline (p < 0.05). Δ: change from baseline; AUC: area under the curve; ISSI: insulin secretion sensitivity index; HOMA-β: homeostatic model assessment of β-cell function; CPI: C-peptide reactivity index; SUIT: the secretory unit of islet in transplantation index; IGI: insulinogenic index; PI/IRI: ratio of proinsulin to immunoreactive insulin; HOMA-IR: homeostatic model assessment of insulin resistance.
respectively. There was significant reduction from baseline to end of treatment in fasting plasma insulin, 30-minute postprandial insulin levels was observed for group A in comparison with group B.


diabetes between group A and group B (P > 0.05). A similar significant reduction from baseline to end of treatment in glycated albumin (−6.44 ± 3.23% and −6.42 ± 3.56%) and HbA1c levels (−0.94 ± 0.50% [−10.3 mmol/mol] and −0.80 ± 0.35% [−8.7 mmol/mol]) was observed for groups A and B, respectively (Table 1). After reaching glycemic targets, the basal and bolus insulin doses of group A were 20.3 ± 5.6 U and 25.5 ± 5.9 U, respectively, while the median dose of metformin and gliclazide and mean insulin dose in group B were 1.0 g/day, 60 mg/day, and 17.9 ± 6.7 U, respectively. Twenty-four patients (72.7%) took gliclazide and mean insulin dose in both treatment groups (Table 1). For HDL-C and triglycerides, a significant decrease in LDL-C and total cholesterol levels in both treatment groups was only seen for group B (P < 0.01), although no significant differences in the change in lipid levels were observed between the treatment groups.

3.2. Glycemic Control and Lipid Profiles. The time to achieve glycemic target (3.6 ± 1.2 days vs. 4.0 ± 1.4 days) and duration of treatment (10.5 ± 1.7 days vs. 10.6 ± 1.8 days) were similar for subjects in group A and group B (P > 0.05). A smaller reduction in mean basal and bolus insulin doses of group A were 1.7 days vs. 10.6 ± 20.3 ± 5.9 U, respectively, while the median dose of basal insulin glargine plus oral hyperglycemic agent (group B) (P < 0.05, **P < 0.01).

3.3. Glycemic Excursions. Similar levels of glycemic excursions were observed after treatment in CSII versus basal insulin plus OHAs for controlling (Table 3); MAGE was 3.40 ± 1.40 mmol/L for group A and 3.16 ± 1.38 mmol/L for group B (P = 0.484). After adjusted with mean capillary blood glucose (seven-point/day) at baseline (by using ANCOVA), the estimated MAGE was 3.44 ± 0.23 mmol/L for group A and 3.12 ± 0.24 mmol/L for group B, respectively (P = 0.352). Other measures of glucose fluctuations including SDBG, frequency of glycemic excursion (FGE), mean of daily differences (MODD), and AUC < 3.9 values were also comparable between treatment groups, although the AUC > 7.8 was significantly lower for group B (P = 0.003). Continuous glucose monitoring showed that the preprandial 1-hour MBG level was significantly lower for patients in group B before breakfast (P = 0.004), lunch (P = 0.047), and dinner (P = 0.002), and the postprandial 3-hour MBG level after lunch (P = 0.021) was also lower for group B. However, the difference between groups was not significant for the 3-hour postprandial MBG level after breakfast and dinner.

3.4. Insulin Resistance and β-Cell Function. Levels of insulin and C-peptide were higher after treatment (P < 0.01) in both groups (Supplementary Figures 2A and 2B). A greater increase in fasting plasma insulin, 30-minute postprandial plasma insulin, and C-peptide levels was seen for group B compared with group A. The AUCs for both insulin and C-peptide during a mixed meal tolerance test were significantly elevated after treatment (both P < 0.01), with no significant difference between groups (P = 0.230 and P = 0.360, respectively). HOMA-IR decreased significantly for both groups (P < 0.01), with no significant differences.
observed between the treatment groups before or after insulin treatment (Table 2).

All β-cell secretion indices improved significantly over the 12-day study period, including HOMA-β, CPI, SUIT, ∆INS0.5h/∆GLU0.5h, and ISSI-2 (all \( p < 0.01 \)), indicating that β-cell function was substantially restored for both treatment groups. Furthermore, the recovery of rapid-phase insulin secretion was comparable for both treatment groups, as shown by the change in ∆INS0.5h/∆GLU0.5h (\( p = 0.06 \)) by the end of treatment. The PI/IRI values decreased significantly (both \( p < 0.01 \)) after treatment for both treatment groups, with no significant intergroup difference (\( p = 0.432 \)).

### 3.5. Effects on BMI and Hypoglycemia

No differences were observed between groups A and B for change in body weight (−0.16 ± 0.089 kg and 0.07 ± 0.072 kg, respectively, \( p = 0.658 \)) or BMI (−0.05 ± 0.02 kg/m\(^2\) and −0.02 ± 0.028 kg/m\(^2\), respectively, \( p = 0.723 \)) during the study. In group A, 19 of 35 patients (54.3%) experienced a total of 27 hypoglycemic events, and no patients experienced severe hypoglycemia; in group B, 22 of 33 patients (66.7%) experienced a total of 42 hypoglycemic events, and no patients experienced severe hypoglycemia. The frequency of hypoglycemia did not differ between groups.

### 4. Discussion

To the authors’ knowledge, this is the first randomized trial to compare the effect of short-term intensive therapy with basal insulin plus OHAs versus CSII in people with newly diagnosed type 2 diabetes mellitus. The results of the study show that individuals treated with both basal insulin plus OHAs and CSII achieve optimal glycemic control within around 4 days. A similar significant reduction from baseline to end of treatment in glycated albumin and Hba1c levels was observed. After reaching the blood glucose target, glucose fluctuations as determined by MAGE, SDBG, FGE, and MODD were similar in both treatment groups. Furthermore, β-cell function was improved with short-term intensive treatment, irrespective of whether basal insulin plus OHAs or CSII was used. These results demonstrate that basal insulin plus OHA therapy may be an effective short-term intensive therapy for relieving hyperglycemia and restoring β-cell function.

In the present study, glycemic excursions, as measured by MAGE, SDBG, and MBG, were similarly controlled with basal insulin plus OHAs and CSII. A previous study of basal insulin monotherapy versus CSII for early intensive treatment of type 2 diabetes reported greater glycemic excursions with basal insulin compared with CSII [21]. This suggests that the addition of OHAs to basal insulin leads to tighter control of blood glucose compared with basal insulin alone. Indeed, this is not surprising given that basal insulin mainly controls FPG, and the addition of metformin or glimepiride would be expected to exert greater control over postprandial blood glucose levels. This finding is important given that PPG excursions have been associated with myocardial infarction and cardiovascular mortality [30]. In addition, tighter control of blood glucose levels is associated with greater reductions in HbA1c and lower incidence of hyper- or hypoglycemia.

Previous studies have shown that administering 2 weeks of CSII to newly diagnosed patients with type 2 diabetes resulted in almost a 1% decrease in HbA1c and an 8% decrease in glycated albumin, while the time taken to achieve glycemic targets was around 3 to 5 days [13, 21]. The results of the present study are comparable regarding the time taken to reach glycemic target for both CSII and basal insulin plus OHAs. This finding indicates that basal insulin glargine plus OHAs is an effective treatment for managing hyperglycemia in newly diagnosed patients with type 2 diabetes mellitus. A major benefit of insulin glargine plus OHA therapy is the

### Table 3: Glycemic excursion parameters at the end of treatment with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B).

| Indices† | Group A (n = 35) | Group B (n = 33) | \( P \) value for group comparison |
|----------|-----------------|-----------------|----------------------------------|
| MAGE (mmol/L) | 3.40 ± 1.40 | 3.16 ± 1.38 | 0.484 |
| SDBG | 1.41 ± 0.53 | 1.21 ± 0.53 | 0.119 |
| FGE† | 3 (3–4) | 3 (3–4) | 0.908 |
| MODD | 1.64 ± 0.55 | 1.54 ± 0.75 | 0.520 |
| AUC < 3.9† | 0.00 (0.00–0.02) | 0.00 (0.00–0.00) | 0.142 |
| AUC > 7.8 | 0.46 ± 0.37 | 0.24 ± 0.18 | 0.003 |
| 1-hour prebreakfast MBG (mmol/L) | 7.11 ± 1.20 | 6.26 ± 1.17 | 0.004 |
| 1-hour prelunch MBG (mmol/L) | 7.24 ± 1.71 | 6.46 ± 1.44 | 0.047 |
| 1-hour predinner MBG (mmol/L) | 7.78 ± 1.58 | 6.69 ± 1.19 | 0.002 |
| 3-hour after breakfast MBG (mmol/L) | 7.56 ± 1.23 | 7.18 ± 1.23 | 0.207 |
| 3-hour after lunch MBG (mmol/L) | 7.84 ± 1.64 | 6.98 ± 1.36 | 0.021 |
| 3-hour after dinner MBG (mmol/L) | 8.08 ± 1.43 | 7.52 ± 1.41 | 0.111 |
| 24-hour MBG (mmol/L) | 7.49 ± 0.96 | 7.02 ± 1.03 | 0.056 |

† Data are mean (standard deviation) unless otherwise stated. †Median (range) AUC > 7.8 mmol/L, area under the curve above 7.8 mmol/L; AUC < 3.9 mmol/L, area under the curve below 3.9 mmol/L. MBG: mean blood glucose; SDBG: standard deviation of blood glucose; MAGE: mean amplitude of glycemic fluctuations; FGE: frequency of glycemic excursion; MODD: mean of daily differences.
single daily insulin injection. Patient adherence to therapy is a key factor for achieving glycemic control, and the difficulty in managing multiple injections and multiple daily glucose measurements represents a major barrier to compliance [31]. The importance of adherence to medication has been evaluated in a number of prospective and retrospective studies [32, 33], which show that glycemic control rates improve progressively with better medication compliance. In this regard, insulin glargine plus OHA treatment may be expected to result in better compliance than requiring patients to administer twice-daily insulin.

Previous studies reported that rapid correction of hyperglycemia, or so-called glucotoxicity, by short-term intensive therapies, has substantial benefits in terms of promoting islet cell functional recovery through “β-cell rest” [12, 13, 21]. In this study, CPI, SUIT, and ISSI-2 were used to measure endogenous insulin secretion; these methods correlate well with the glucose clamp test and are widely used in studies assessing β-cell function. Data from the present study suggest that basal insulin plus OHA therapy rapidly corrects hyperglycemia and also confers β-cell function benefits, possibly by eliminating glucotoxicity and providing a β-cell rest period. In addition, several studies have been conducted to assess the effect of neutralising glucotoxicity through short-term (2–3 weeks) intensive antihyperglycemic treatment on improving insulin resistance. A 2013 meta-analysis of such studies reported a reduction in HOMA-IR of −0.57 (95% CI; −0.84 to −0.29) [12]. This is in close agreement with the reduction in HOMA-IR achieved with CSII over 12 days in the present study (−0.56), although individuals who received basal insulin plus OHA achieved a slightly lower reduction (−0.33). However, it is known that remission rates differ for patients receiving total exogenous insulin replacement by CSII or MDI and those receiving agents that promote endogenous insulin secretion such as oral sulfonylureas, indicating that besides glycotoxicity there are likely to be other factors that affect β-cell function [13]. As such, further studies are required to compare remission rates following intensive short-term CSII or basal insulin plus OHAs.

The recovery of first-phase insulin secretion and decreased PI/IRI ratio has been confirmed for both short-term intensive insulin and oral medication therapies [13]. However, there has been controversy over the effects of sulfonylurea on the PI/IRI ratio, with some studies showing an increase and others a decrease [34–36]. Interestingly, the current study showed that the combination of basal insulin with gliclazide and metformin was able to restore early-phase secretory function and markedly decrease the PI/IRI ratio, indicating improvements in both quantitative and qualitative insulin production.

The primary limitation of this study was that only the short-term benefits of intensive insulin treatment were investigated, which does not allow for long-term observations. Second, the study was conducted at a single center and had small sample size. Third, MAGE could not be adjusted for baseline differences between the groups because of the absence of baseline measurement of MAGE. However, there was no statistical difference between mean seven-point blood glucose at baseline in two groups ($p > 0.05$). After adjusted for mean blood glucose at baseline, the estimated MAGE was similar in two groups ($p = 0.352$). These results suggested that glycemic excursions were comparable between two groups. Despite these limitations, the demonstration that basal plus OHA therapy is able to restore glycemic control and improve β-cell function warrants further investigation.

In conclusion, short-term intensive therapy with basal insulin plus OHAs showed comparable benefits to CSII in terms of overall glycemic control and improvement in β-cell function in newly diagnosed patients with type 2 diabetes mellitus and is a possible option for treating newly diagnosed patients with type 2 diabetes.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Shuo Lin and Mu Chen contributed equally to this paper.

**Acknowledgments**

This work was funded by the Science and Technology Project of Guangzhou City (2014Y2-00072), the Science and Technology Planning Project of Guangdong Province (2013B021800198, 2017A020215026), and the Medical Scientific Research Foundation of Guangdong Province (A2017314). Third party editorial support was provided by Adelphi and paid for by Sanofi.

**Supplementary Materials**

Supplementary Figure 1: patients’ flow diagram. Supplementary Figure 2: changes in insulin (A) and C-peptide (B) levels during a standard meal in the two study groups, at the end of treatment with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B). Supplementary: the titration algorithm of basal insulin in group B. (Supplementary Materials)

**References**

[1] B. L. Wajchenberg, “Clinical approaches to preserve β-cell function in diabetes,” Advances in Experimental Medicine and Biology, vol. 654, pp. 515–535, 2010.

[2] G. M. Reaven, “HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not,” Diabetes and Vascular Disease Research, vol. 6, no. 2, pp. 133–138, 2009.

[3] W. El-Assaad, J. Buteau, M. L. Peyrot et al., “Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death,” Endocrinology, vol. 144, no. 9, pp. 4154–4163, 2003.
[4] R. R. Holman, “Assessing the potential for α-glucosidase inhibitors in prediabetic states,” *Diabetes Research and Clinical Practice*, vol. 40, Supplement 1, pp. S21–S25, 1998.

[5] The DCCT/EDIC Research Group, L. P. Aiello, W. Sun et al., “Intensive diabetes therapy and ocular surgery in type 1 diabetes,” *The New England Journal of Medicine*, vol. 372, no. 18, pp. 1722–1733, 2015.

[6] R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-year follow-up of intensive glucose control in type 2 diabetes,” *The New England Journal of Medicine*, vol. 359, no. 15, pp. 1577–1589, 2008.

[7] K. J. Hunt, N. L. Baker, P. A. Cleary et al., “Longitudinal association between endothelial dysfunction, inflammation, and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: an evaluation of the DCCT/EDIC cohort,” *Diabetes Care*, vol. 38, no. 7, pp. 1281–1289, 2015.

[8] J. Frias, B. W. Bode, T. S. Bailey, M. S. Kipnes, R. Brunelle, and S. V. Edelman, “A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections,” *Journal of Diabetes Science and Technology*, vol. 5, no. 4, pp. 887–893, 2011.

[9] Y. Reznik, J. Morera, A. Rod et al., “Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up,” *Diabetes Technology & Therapeutics*, vol. 12, no. 12, pp. 931–936, 2010.

[10] J. C. Pickup and E. Renard, “Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes,” *Diabetes Care*, vol. 31, Supplement 2, pp. S140–S145, 2008.

[11] Y. Reznik, O. Cohen, R. Aronson et al., “Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (Opt2mise): a randomised open-label controlled trial,” *The Lancet*, vol. 384, no. 9950, pp. 1265–1272, 2014.

[12] C. K. Kramer, B. Zinman, and R. Retnakaran, “Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis,” *The Lancet Diabetes & Endocrinology*, vol. 1, no. 1, pp. 28–34, 2013.

[13] J. Weng, Y. Li, W. Xu et al., “Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial,” *The Lancet*, vol. 371, no. 9626, pp. 1753–1760, 2008.

[14] E. A. Ryan, S. Imes, and C. Wallace, “Short-term intensive insulin therapy in newly diagnosed type 2 diabetes,” *Diabetes Care*, vol. 27, no. 5, pp. 1028–1032, 2004.

[15] J. L. Colquitt, C. Green, M. K. Sidhu, D. Hartwell, and N. Waugh, “Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes,” *Health Technology Assessment*, vol. 8, no. 43, 2004.

[16] N. Hermanns, B. Kulzer, T. Kohlmann et al., “Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial,” *Health and Quality of Life Outcomes*, vol. 13, no. 1, p. 77, 2015.

[17] S. Tsukube, Y. Ikeda, T. Kadawaki, and M. Odawara, “Improved treatment satisfaction and self-reported health status after introduction of basal-supported oral therapy using insulin glargine in patients with type 2 diabetes: sub-analysis of ALOHA2 study,” *Diabetes Therapy*, vol. 6, no. 2, pp. 153–171, 2015.

[18] M. R. Lankisch, S. del Prato, M. P. Dain, P. Mullins, and D. R. Owens, “Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: a pooled analysis of four clinical trials,” *Primary Care Diabetes*, vol. 10, no. 1, pp. 51–59, 2016.

[19] V. Fonseca, J. Gill, R. Zhou, and J. Leahy, “An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia,” *Diabetes, Obesity and Metabolism*, vol. 13, no. 9, pp. 814–822, 2011.

[20] S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes,” *Diabetes Care*, vol. 38, no. 1, pp. 140–149, 2015.

[21] L. Zeng, H. Lu, H. Deng, P. Mu, X. Li, and M. Wang, “Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment,” *Diabetes Technology & Therapeutics*, vol. 14, no. 1, pp. 35–42, 2012.

[22] WHO, *Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part I, Diagnosis and Classification of Diabetes Mellitus*, World Health Organization, Geneva, Switzerland, 1999.

[23] D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man,” *Diabetologia*, vol. 28, no. 7, pp. 412–419, 1985.

[24] M. Matsuda and R. A. DeFronzo, “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp,” *Diabetes Care*, vol. 22, no. 9, pp. 1462–1470, 1999.

[25] Y. Yamada, K. Fukuda, S. Fujimoto et al., “SUIIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes,” *Diabetes Research and Clinical Practice*, vol. 74, no. 3, pp. 222–226, 2006.

[26] J. B. L. Hoekstra, H. J. M. Van Rijn, J. H. H. Thijssen, and D. W. Erkelens, “C-peptide reactivity as a measure of insulin dependency in obese diabetic patients treated with insulin,” *Diabetes Care*, vol. 5, no. 6, pp. 585–591, 1982.

[27] H. S. Selzter, E. W. Allen, A. L. Herron Jr., and M. T. Brennan, “Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus,” *The Journal of Clinical Investigation*, vol. 46, no. 3, pp. 323–335, 1967.

[28] C. K. Kramer, H. Choi, B. Zinman, and R. Retnakaran, “Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 305, no. 11, pp. E1398–E1407, 2013.

[29] F. J. Service, G. D. Molnar, J. W. Rosevear, E. Ackerman, L. C. Gatewood, and W. F. Taylor, “Mean amplitude of glycemic excursions, a measure of diabetic instability,” *Diabetes*, vol. 19, no. 9, pp. 644–655, 1970.

[30] M. Hanefeld, S. Fischer, U. Julius et al., “Risk factors for myocardial infarction and death in newly detected NIDDM: the
Diabetes Intervention Study, 11-year follow-up,” *Diabetologia*, vol. 39, no. 12, pp. 1577–1583, 1996.

[31] W. T. Cefalu, “Evaluation of alternative strategies for optimizing glycemia: progress to date,” *The American Journal of Medicine*, vol. 113, no. 6, pp. 23–35, 2002.

[32] S. A. Doggrell and S. Warot, “The association between the measurement of adherence to anti-diabetes medicine and the HbA1c,” *International Journal of Clinical Pharmacy*, vol. 36, no. 3, pp. 488–497, 2014.

[33] Y. Rozenfeld, J. S. Hunt, C. Plauschinat, and K. S. Wong, “Oral antidiabetic medication adherence and glycemic control in managed care,” *The American Journal of Managed Care*, vol. 14, no. 2, pp. 71–75, 2008.

[34] T. Ohkura, K. Inoue, Y. Fujikoa et al., “The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study,” *BMC Research Notes*, vol. 6, no. 1, p. 453, 2013.

[35] B. L. Wajchenberg, A. T. M. G. Santomauro, and R. N. Porrelli, “Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM),” *Diabetes Research and Clinical Practice*, vol. 20, no. 2, pp. 147–154, 1993.

[36] S. A. Smith, L. E. Porter, N. Biswas, and M. I. Freed, “Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin: insulin ratio in type 2 diabetes,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 89, no. 12, pp. 6048–6053, 2004.